Press Releases

Date Headline
9/16/2021
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
 Summary
Confirmed objective response rate (cORR) of 75% overall and   93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP) Median duration of response (mDOR) of 16.4 months and median progression free survival (mPFS) of 12 months Data support zanidatamab + chemotherapy as the foundation of a  Continue Reading
9/12/2021
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
 Summary
Abstract data demonstrate encouraging antitumor activity in first-line GEA Full ESMO presentation available September 16 at 8:30 am CEST , 2:30 am ET Conference call and webcast with principal investigator, Dr. Geoffrey Ku , on September 16 at 7:30 am ET VANCOUVER, British Columbia --(BUSINESS  Continue Reading
8/4/2021
Zymeworks Reports 2021 Second Quarter Financial Results
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Aug. 4, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2021 .  Continue Reading
8/3/2021
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Aug. 3, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, Inc. (Janssen) dosed the first patient with JNJ-78278343, a bispecific antibody  Continue Reading
7/28/2021
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Jul. 28, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combination with Tukysa ® (tucatinib) and  Continue Reading
7/8/2021
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Jul. 8, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Ladenburg Thalmann Healthcare Conference on July 14, 2021  Continue Reading
5/26/2021
Zymeworks to Present at Jefferies Virtual Healthcare Conference
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.  Continue Reading
5/6/2021
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders  Continue Reading
5/5/2021
Zymeworks Reports 2021 First Quarter Financial Results
 Summary
Download the PDF version PDF Format (opens in new window) ANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2021.  Continue Reading
4/19/2021
Zymeworks Announces Succession Plan for Chief Medical Officer
 Summary
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Diana Hausman, M.D., will be transitioning out of her role as Zymeworks’ Chief Medical Officer (CMO) and assuming  Continue Reading
Displaying 1 - 10 of 20
Copyright 2021 , Zymeworks Inc.